Since AD is a clinically heterogeneous disease, it is of extreme relevance to better identify the subtypes of AD, which will profit the most from the current and future specific therapies, including monoclonal antibodies directed to T cell cytokines such as IL-4, IL-13, and IL-31, for the best individualized benefit. Here, IL13 is linked to Alzheimer disease.